ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-994-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.76 million
Profitability
Miscellaneous
Employees36
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) released its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.08). The biotechnology company had revenue of $2.94 million for the quarter, compared to the consensus estimate of $1.81 million. ArQule had a negative return on equity of 30.51% and a negative net margin of 60.09%. View ArQule's Earnings History.
When is ArQule's next earnings date?
What guidance has ArQule issued on next quarter's earnings?
ArQule updated its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of $-0.39--0.37 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-0.34. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $5.6 million.
What price target have analysts set for ARQL?
5 brokerages have issued 12 month price objectives for ArQule's stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate ArQule's share price to reach $7.50 in the next year. This suggests a possible upside of 55.6% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
Has ArQule been receiving favorable news coverage?
Headlines about ARQL stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ArQule earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the next several days.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Insmed (INSM), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), AnaptysBio (ANAB), The Medicines (MDCO), Supernus Pharmaceuticals (SUPN), Mallinckrodt (MNK), Endocyte (ECYT), Endo International (ENDP) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of ArQule own?
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 58)
- Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 56)
- Mr. Robert J. Weiskopf, CFO & Treasurer (Age 68)
- Dr. Brian Schwartz, Chief Medical Officer (Age 57)
- Ms. Dawn Schottlandt, VP of Investor Relations & Corp. Communications
Who are ArQule's major shareholders?
ArQule's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.91%), Millennium Management LLC (3.65%), Sphera Funds Management LTD. (1.86%), Northern Trust Corp (1.14%), Geode Capital Management LLC (1.09%) and Geode Capital Management LLC (1.09%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which major investors are selling ArQule stock?
ARQL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Opaleye Management Inc., Acadian Asset Management LLC, Bailard Inc., MetLife Investment Advisors LLC, Squarepoint Ops LLC, CAPROCK Group Inc. and Northern Trust Corp. View Insider Buying and Selling for ArQule.
Which major investors are buying ArQule stock?
ARQL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Two Sigma Investments LP, California Public Employees Retirement System, D. E. Shaw & Co. Inc., Chicago Equity Partners LLC, Dupont Capital Management Corp and Bank of New York Mellon Corp. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $4.82.
How big of a company is ArQule?
ArQule has a market capitalization of $525.40 million and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.
What is ArQule's official website?
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
